Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood Pressure

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: TAK-536

First Posted Date: 2020-12-16

Last Posted Date: 2024-12-09

Lead Sponsor: Takeda

Target Recruit Count: 10

Registration Number: NCT04668157

Locations: 🇯🇵
National Hospital Organization Kanazawa Medical Center, Kanazawa, Ishikawa, Japan
🇯🇵
Miyagi Children's Hospital, Sendai, Miyagi, Japan
🇯🇵
Hiroshima Prefectural Hospital, Hiroshima, Japan

and more 16 locations

A Study to Collect Information of People With Narcolepsy in Spain

Completed

Conditions: Narcolepsy

First Posted Date: 2020-12-14

Last Posted Date: 2024-10-04

Lead Sponsor: Takeda

Target Recruit Count: 214

Registration Number: NCT04667338

Locations: 🇪🇸
Hospital Clinic de Barcelona, Barcelona, Cataluna, Spain

A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice

Completed

Conditions: Multiple Myeloma
Immunoglobulin Light-chain Amyloidosis

First Posted Date: 2020-12-09

Last Posted Date: 2024-07-08

Lead Sponsor: Takeda

Target Recruit Count: 240

Registration Number: NCT04659798

Locations: 🇪🇸
H. Universitari Son Espases, Palma de Mallorca, Islas Baleares, Spain
🇪🇸
Hospital General Universitario Santa Lucia, Cartagena, Murcia, Spain
🇪🇸
H. Universitario de Leon, Leon, Castilla Y Leon, Spain

and more 11 locations

A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema

Phase 3

Completed

Conditions: Hereditary Angioedema

Interventions: Drug: TAK-667

First Posted Date: 2020-12-04

Last Posted Date: 2022-03-29

Lead Sponsor: Takeda

Target Recruit Count: 2

Registration Number: NCT04654351

Locations: 🇯🇵
Aich Medical University Hospital, Nagakute, Aichi, Japan
🇯🇵
Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan
🇯🇵
Kagoshima University Hospital, Kagoshima, Japan

Paricipant Preferences in the Treatment of Inflammatory Bowel Disease (IBD) in Europe

Completed

Conditions: Inflammatory Bowel Diseases
Crohn Disease
Colitis, Ulcerative

First Posted Date: 2020-10-22

Last Posted Date: 2021-02-11

Lead Sponsor: Takeda

Target Recruit Count: 686

Registration Number: NCT04597905

Locations: 🇫🇷
Carenity, Paris, France

A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South Korea

Completed

Conditions: Ovarian Neoplasms

First Posted Date: 2020-10-19

Last Posted Date: 2024-12-11

Lead Sponsor: Takeda

Target Recruit Count: 662

Registration Number: NCT04589039

Locations: 🇰🇷
Inje University Haeundae Paik Hospital, Busan, Korea, Republic of

A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung
Anaplastic Lymphoma Kinase

Interventions: Other: No Intervention

First Posted Date: 2020-10-19

Last Posted Date: 2023-10-12

Lead Sponsor: Takeda

Target Recruit Count: 616

Registration Number: NCT04592523

Locations: 🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of

Study of TAK-672 in Participants With Acquired Hemophilia A

Phase 2

Completed

Conditions: Acquired Hemophilia A

Interventions: Biological: TAK-672

First Posted Date: 2020-10-08

Last Posted Date: 2024-12-02

Lead Sponsor: Takeda

Target Recruit Count: 5

Registration Number: NCT04580407

Locations: 🇯🇵
Gunma University Hospital, Maebashi, Gunma, Japan
🇯🇵
Nagoya University Hospital, Aichi, Nagoya, Japan
🇯🇵
Nara Medical University Hospital, Kashihara-shi, Nara, Japan

and more 6 locations

A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Phase 2

Withdrawn

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: TAK-788
Drug: Antidiarrheal prophylaxis

First Posted Date: 2020-10-06

Last Posted Date: 2020-12-17

Lead Sponsor: Takeda

Registration Number: NCT04576208

Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes

Completed

Conditions: Crohn Disease
Inflammatory Bowel Diseases
Colitis, Ulcerative

Interventions: Other: No Intervention

First Posted Date: 2020-09-28

Last Posted Date: 2024-03-15

Lead Sponsor: Takeda

Target Recruit Count: 7873

Registration Number: NCT04567628

Locations: 🇨🇦
Takeda Canada, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy